Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 174

1.

Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes.

Ruan Y, Thabit H, Leelarathna L, Hartnell S, Willinska ME, Dellweg S, Benesch C, Mader JK, Holzer M, Kojzar H, Evans ML, Pieber TR, Arnolds S, Hovorka R; AP@home consortium.

Diabetes Care. 2016 Mar 10. pii: dc152623. [Epub ahead of print]

PMID:
26965717
2.

Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial.

Tauschmann M, Allen JM, Wilinska ME, Thabit H, Stewart Z, Cheng P, Kollman C, Acerini CL, Dunger DB, Hovorka R.

Diabetes Care. 2016 Jan 6. pii: dc152078. [Epub ahead of print]

PMID:
26740634
3.

Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons.

Thabit H, Hovorka R.

Expert Opin Drug Deliv. 2016 Mar;13(3):389-400. doi: 10.1517/17425247.2016.1115013. Epub 2015 Nov 30.

PMID:
26618219
4.

The Future of the Artificial Pancreas.

Thabit H, Hovorka R.

Diabetes Technol Ther. 2015 Nov;17(11):763-5. doi: 10.1089/dia.2015.0297. No abstract available.

PMID:
26535927
5.

Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes.

Tauschmann M, Thabit H, Leelarathna L, Elleri D, Allen JM, Lubina-Solomon A, Stadler M, Walkinshaw E, Iqbal A, Choudhary P, Wilinska ME, Heller SR, Amiel SA, Evans ML, Dunger DB, Hovorka R.

J Diabetes Sci Technol. 2015 Oct 7;9(6):1346-7. doi: 10.1177/1932296815604439. No abstract available.

PMID:
26451010
6.

Home Use of an Artificial Beta Cell in Type 1 Diabetes.

Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R; APCam Consortium; AP@home Consortium.

N Engl J Med. 2015 Nov 26;373(22):2129-40. doi: 10.1056/NEJMoa1509351. Epub 2015 Sep 17.

7.

Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes.

Thabit H, Elleri D, Leelarathna L, Allen J, Lubina-Solomon A, Stadler M, Walkinshaw E, Iqbal A, Choudhary P, Wilinska M, Barnard K, Heller S, Amiel S, Evans M, Dunger D, Hovorka R.

Lancet. 2015 Feb 26;385 Suppl 1:S96. doi: 10.1016/S0140-6736(15)60411-1.

PMID:
26312919
8.

Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.

Elleri D, Biagioni M, Allen JM, Kumareswaran K, Leelarathna L, Caldwell K, Nodale M, Wilinska ME, Haidar A, Calhoun P, Kollman C, Jackson NC, Umpleby AM, Acerini CL, Dunger DB, Hovorka R.

Diabetes Obes Metab. 2015 Dec;17(12):1173-9. doi: 10.1111/dom.12549. Epub 2015 Oct 9.

9.

Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions.

Thabit H, Leelarathna L, Wilinska ME, Elleri D, Allen JM, Lubina-Solomon A, Walkinshaw E, Stadler M, Choudhary P, Mader JK, Dellweg S, Benesch C, Pieber TR, Arnolds S, Heller SR, Amiel SA, Dunger D, Evans ML, Hovorka R.

Diabetes Technol Ther. 2015 Nov;17(11):801-7. doi: 10.1089/dia.2015.0062. Epub 2015 Aug 4.

10.

Perioperative Tight Glucose Control Reduces Postoperative Adverse Events in Nondiabetic Cardiac Surgery Patients.

Bláha J, Mráz M, Kopecký P, Stříteský M, Lipš M, Matias M, Kunstýř J, Pořízka M, Kotulák T, Kolníková I, Šimanovská B, Zakharchenko M, Rulíšek J, Šachl R, Anýž J, Novák D, Lindner J, Hovorka R, Svačina Š, Haluzík M.

J Clin Endocrinol Metab. 2015 Aug;100(8):3081-9. doi: 10.1210/jc.2015-1959. Epub 2015 Jun 16.

PMID:
26079777
11.

Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart.

Goudie RJ, Hovorka R, Murphy HR, Lunn D.

Stat Med. 2015 Oct 15;34(23):3144-58. doi: 10.1002/sim.6536. Epub 2015 May 26.

12.

Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery.

Ruan Y, Thabit H, Wilinska ME, Hovorka R.

Biomed Eng Online. 2015 Mar 4;14:19. doi: 10.1186/s12938-015-0009-5.

13.

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.

Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E.

Diabetes Metab Res Rev. 2016 Jan;32(1):21-39. doi: 10.1002/dmrr.2653. Epub 2015 Jun 22. Review.

PMID:
25865292
14.

Holistic Impact of Closed-Loop Technology on People With Type 1 Diabetes.

Young AJ, Thabit H, Heller SR, Evans ML, Amiel SA, Hovorka R, Barnard KD.

J Diabetes Sci Technol. 2015 Jul;9(4):932-3. doi: 10.1177/1932296815580162. Epub 2015 Apr 7. No abstract available.

15.

Artificial Pancreas Project at Cambridge 2013.

Hovorka R.

Diabet Med. 2015 Aug;32(8):987-92. doi: 10.1111/dme.12766. Epub 2015 Apr 15. Review.

PMID:
25819473
16.

Quantifying the acute changes in glucose with exercise in type 1 diabetes: a systematic review and meta-analysis.

García-García F, Kumareswaran K, Hovorka R, Hernando ME.

Sports Med. 2015 Apr;45(4):587-99. doi: 10.1007/s40279-015-0302-2. Review.

PMID:
25616852
17.

Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting.

Barnard KD, Wysocki T, Thabit H, Evans ML, Amiel S, Heller S, Young A, Hovorka R; Angela Consortium.

Diabet Med. 2015 May;32(5):601-8. doi: 10.1111/dme.12706. Epub 2015 Feb 20.

PMID:
25615888
18.

Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.

Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, Hovorka R.

Diabetologia. 2015 Apr;58(4):687-90. doi: 10.1007/s00125-014-3483-6. Epub 2014 Dec 24.

19.

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength.

Elleri D, Allen JM, Tauschmann M, El-Khairi R, Benitez-Aguirre P, Acerini CL, Dunger DB, Hovorka R.

BMJ Open Diabetes Res Care. 2014 Dec 11;2(1):e000040. doi: 10.1136/bmjdrc-2014-000040. eCollection 2014.

20.

Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.

Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M, Walkinshaw E, Iqbal A, Choudhary P, Wilinska ME, Barnard KD, Heller SR, Amiel SA, Evans ML, Dunger DB, Hovorka R.

Diabetes Obes Metab. 2015 May;17(5):452-8. doi: 10.1111/dom.12427. Epub 2015 Jan 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk